Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Herpes Labialis (Oral Herpes) Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Herpes Labialis (Oral Herpes) Overview | 8 | 1 |
| Pipeline Products for Herpes Labialis (Oral Herpes) Comparative Analysis | 9 | 1 |
| Herpes Labialis (Oral Herpes) Therapeutics under Development by Companies | 10 | 1 |
| Herpes Labialis (Oral Herpes) Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Herpes Labialis (Oral Herpes) Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Herpes Labialis (Oral Herpes) Products under Development by Companies | 15 | 1 |
| Herpes Labialis (Oral Herpes) Products under Investigation by Universities/Institutes | 16 | 1 |
| Herpes Labialis (Oral Herpes) Companies Involved in Therapeutics Development | 17 | 9 |
| AiCuris GmbH and Co KG | 17 | 1 |
| Beech Tree Labs, Inc. | 18 | 1 |
| Foamix Pharmaceuticals Ltd. | 19 | 1 |
| Mymetics Corporation | 20 | 1 |
| NanoViricides, Inc. | 21 | 1 |
| Onxeo SA | 22 | 1 |
| Shulov Innovative Science Ltd. | 23 | 1 |
| TGV-Laboratories | 24 | 1 |
| Vironova AB | 25 | 1 |
| Herpes Labialis (Oral Herpes) Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 14 |
| acyclovir Drug Profile | 35 | 2 |
| acyclovir Drug Profile | 37 | 1 |
| Aspidasept Drug Profile | 38 | 1 |
| B-220 Drug Profile | 39 | 1 |
| BTL-TMLHSV Drug Profile | 40 | 2 |
| herpes simplex virus [type 1, 2] (virus like particle) vaccine Drug Profile | 42 | 1 |
| herpes simplex virus [type 1, 2] vaccine Drug Profile | 43 | 1 |
| pritelivir Drug Profile | 44 | 2 |
| Small Molecule for Cold Sores Drug Profile | 46 | 1 |
| Teg-379 Drug Profile | 47 | 1 |
| ZEP-3 Drug Profile | 48 | 1 |
| Herpes Labialis (Oral Herpes) Dormant Projects | 49 | 1 |
| Herpes Labialis (Oral Herpes) Discontinued Products | 50 | 1 |
| Herpes Labialis (Oral Herpes) Product Development Milestones | 51 | 8 |
| Featured News &Press Releases | 51 | 1 |
| Feb 16, 2016: Cipher Pharmaceuticals announces Sitavig accepted for review by Health Canada | 51 | 1 |
| Jul 21, 2014: BioAlliance Pharma announces the launch of Sitavig in the United States by its partner Innocutis and the granting of a new U.S. Sitavig patent | 51 | 1 |
| Jul 10, 2013: BioAlliance Pharma expands and strengthens its industrial property assets with two patent grants | 52 | 1 |
| May 27, 2013: BioAlliance Pharma Presents Results Of Sitavig At 10th EADV Symposium | 52 | 1 |
| Apr 15, 2013: BioAlliance Pharma's Sitavig Receives US Marketing Authorization For Treatment Of Herpes Labialis | 53 | 1 |
| Apr 04, 2013: Beech Tree Labs Successfully Completes IND Phase I/IIa Oral Herpes Clinical Trial | 54 | 1 |
| Jul 26, 2012: BioAlliance Pharma Receives US Patent Covering Sitavig | 54 | 1 |
| May 29, 2012: BioAlliance Announces Receivability Of Sitavig US Registration Dossier | 55 | 1 |
| Oct 05, 2011: BioAlliance Submits Sitavir European Registration Dossier Through European Decentralized Procedure | 55 | 1 |
| Feb 07, 2011: BioAlliance Pharma Presents Results Of International Survey Performed With Nielsen In Patients Suffering From Herpes Labialis | 56 | 1 |
| Nov 17, 2010: BioAlliance Pharma Presents Pharmacokinetic Results Of Sitavir At AAPS Annual Meeting | 56 | 1 |
| Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress | 57 | 1 |
| Sep 14, 2010: Beech Tree Labs Initiates Phase I/IIa Oral Herpes Trial | 57 | 1 |
| Sep 07, 2010: BioAlliance Pharma Receives European Patent For Acyclovir Lauriad | 58 | 1 |
| Aug 26, 2010: BioAlliance Pharma Plans To Submit Acyclovir Lauriad NDA | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |